skip to Main Content

“Resoil” presented by Envit Ltd.

ReSoil® is internationally patented, groundbreaking remediation solution that enables closed-loop removal of heavy metals from contaminated soils through a zero-emission process with no wastewater, while preserving soil as a natural substrate.

PROBLEM

• Soil contamination with heavy metals is a global problem.
• Heavy metals include toxic metals such as lead (Pb), cadmium (Cd), copper (Cu) and zinc (Zn) as well as toxic metalloids such as arsenic (As) and antimony (Sb).
• Soils absorb decades of pollution from industry, intensive agriculture, traffic, waste, etc. Heavy metals are not degradable and remain in the soil.
• According to a recent conservative estimate, there are 2.8 million potentially contaminated sites in the EU (EEA, 2023).
• In China, 1/6 of the total cultivated area is contaminated with heavy metals (Yao et al., Proc Env Sci 2012, 16, 722-729).
• In New York, 71% of garden soils exceed the limits for lead and arsenic (Chenget al., Soil Sci 2015, 180, 167-174).
• Arsenic and lead are the 1st and 2nd most dangerous environmental pollutants
(ATSDR 2017).Lead distribution in surface soil of the conterminous United States (USGS 2014).
• Arsenic is highly toxic, long-term exposure can cause cancer.
• Lead is a neurotoxin; in the USA, the average lead-related loss of cognitive ability was 2.6 IQ points per person as of
2015 (McFarland et al. PNAS 2022, 119, e2118631119

For more details about technology: Click Here

Patent Application Number: WO2022184903

Machine to Dispose off used Sanitary napkins chemically

Current methods of disposal and associated danger

1. Flushing and burying

• leads to blockages, plumbing problems
• outer layer of sanitary napkin is non-degradable
• collection of napkins in heaps block the pipeline
• pollute streams and rivers
• causes hormonal changes in wildlife – enable harmful organisms in the food chain

2. Incineration

• Harmful gas emissions: dioxin, furan, nitrogen oxides, sulphur dioxide, hydrochloric acid, mercury
• Ash produced contain heavy metals like lead, cadmium, copper, zinc
• Dioxins: cancer, immune system damage, reproductive and developmental problems.
• Halogenated hydrocarbons, acid gases – impair lung function.

Objectives of the new machine

• Disposal of sanitary napkins properly, thereby wiping out the risks involved in flushing, burying, and incineration.
• Reduce pollution and health hazards of conventional methods of sanitary waste disposal.
• Reduce cost for proper disposal of sanitary napkins, tampons, baby diapers and under pads.
• Simplify the process of sanitary waste disposal.
• Help in solving greatest problem people face daily.

Machine to dispose of Uses Sanitary NapkinKey Points of the machine

• One machine- can be used for sanitary napkins, tampons, baby diapers and under pads. (If a method to choose the option while
using the machine is implemented)
• Can be manufactured both – domestic (for households) and industrial size (waste disposal plants/ panchayats)

Patent Application Number: 298227

For more details about technology: Click Here

DIABETES CARE – MEDICAL DEVICE FOR TISSUE OXIMETRY

The Opportunity

Diabetes are Mediial DeviceBlackhawk Technologies, LLC is exclusively representing HyperMed Imaging Inc. (the“Company”) to monetize its’ assets related to a Medical Device for Tissue Oximetry for Diabetes Care. The offering includes an FDA cleared product used by clinicians and backed by 24 patent families comprising of 62 total assets.

The Company’s pioneering technology has been in service since 2006 and has been validated in third-party published papers that assessed oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue for diabetic patients. The Company’s FDA 510(k) cleared product, Hyper View™, quickly determines levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation in superficial tissue in a small and portable configuration.

The Company seeks a strategic acquirer/licensee with both resources and channels to fully commercialize Company’s IP assets.

The Unmet Medical Need

Most medical exams need quick and accurate determination of superficial tissue oxygenation. For example, complications in diabetes and/or peripheral arterial disease increases risk of lower limb ischemia, chronic wounds, amputation or even death.

• Over 420 million people worldwide (1 in 11 people) have diabetes and the number is increasing rapidly.
• More than 29 million Americans have diabetes. Another 86 million have prediabetes, which is 1 in 3 US adults.
• 8.5 million Americans have peripheral arterial disease and among them nearly 2 million people in the USA are living with limb loss.
• The main causes are vascular disease (54%), including diabetes and peripheral arterial disease.
• Approximately 185,000 amputations occur in the United States each year, costing over $8 billion.
• People with diabetes are at greater risk for severe peripheral arterial disease and are five times more likely to require an amputation.
• It is estimated that a low

Hyperspectral Imaging Benefits

• Non-contact color-coded images depicting concentrations of oxyhemoglobin & deoxyhemoglobin, and oxygen saturation without injectable contrast agents.
• Readings are predictive of wound healing and can be used in screening for peripheral vascular disease.
• Software tools allow clinicians to analyze specified areas within the image to localize ischemic tissue.
• Offers improved patient care with speed, ease of use, and clinical efficiency without injectable contrast or physical contact of the device with the patient.
• Safe, using visible light and spectrometer imaging to quantify light absorption in hemoglobin molecules for rapid analysis without leaving the exam room.

For more details about technology: Click Here

IONOJET TM

origion corporate Has developed a proprietary device (“IonojetTM”) that generates nitric oxide (“NO”) from atmospheric air in the form of a high-energy plasma/NO stream and delivers it to targeted locations of the body.

The plasma/NO stream has been shown in investigations to date:

(i)to be non-toxic

(ii) to generate NO activity up to 3 cm below the skin

(iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy, and

(iv) to penetrate and disrupt biofilm

Has identified over 40 target indications in seven clinical areas based on NO’s recognized ability to:

  • Increase blood flow
  • Destroy pathogens (bacterial, viral and fungal)
  • Regenerate tissue
  • Control pain and inflammation

Has completed a dose-ranging feasibility clinical trial in the U.S. for initial target indication (Diabetic Foot Ulcers, “DFU”) to identify optimal dose & demonstrate preliminary safety/efficacy data for the device.

  • Has completed PoC studies in certain target indications
  • Intends to initiate PoC studies in a number of additional indications

For more details about technology: Click Here

Nutrition Innovation In Singapore

nucaneWhite refined sugar is almost pure sucrose. This sucrose is consistently shown in research to be quickly absorbed into the blood stream causing rises in blood sugar levels. This in turn has contributed to the global obesity and diabetes crisis.

The Nucane™ specification of raw sugar is scientifically tested to ensure that this absorption is reduced.What the unique Nucane™ process achieves is to retain at a high level the natural organics, antioxidants and polyphenols that exist in raw sugar cane, delivering a carbohydrate that is less processed, less refined, and which has been demonstrated scientifically to reduce the metabolism of sugar into the blood stream when consumed. This means that it is a low glycemic sugar when tested to the internationally agreed ISO 26442:2010 method.Just as importantly, our technology system ensures that Nucane™ is precise and consistent at industrial scale in primary sugar mills around the world. By eliminating the refining process and applying the Nucane technology at sugar mills, Nucane™ is a less processed, less refined, high in polyphenols specification of raw sugar which has been tested to be low glycemic to international standards.

For more details about technology: Click here

Pop Test & Palisades Therapeutics Companies

Wellness ScreeningWELLNESS Screening/Monitoring

Diabetes

Diagnosed and undiagnosed diabetes in the United States, all ages, 2012, Total: 29.1 million people or 9.3% of the population have diabetes. Diagnosed: 21.0 million people. Undiagnosed: 8.1 million people. (27.8% of people with diabetes are undiagnosed)

NASH/NAFLD

Prevalence of NAFLD and NASH is higher than estimated previously. Hispanics and patients with diabetes are at greatest risk for both NAFLD and NASH. Up to 80% of obese people have the disease. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause. About 12 to 25% of people in the United States has NAFLD. While NASH affects between 2 to 5% of people in the United States.

Cholesterol

Percent of adults age 20 years and over with high serum total cholesterol (greater than or equal to 240 mg/dL): 13.4% (2009-2012)

Gout

Gout prevalence swells in U.S. over last two decades; Increase in obesity and hypertension are likely contributors. Prevalence of gout in the United States has risen over the last twenty years and now affects 8.3 million Americans.

For more details about technology: Click here

Back To Top